Actively Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Led by Incyte Corporation · Updated on 2026-05-04
280
Participants Needed
22
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and tolerability of INCA036873 in adults with advanced solid tumors and blood cancers, including clear cell renal cell carcinoma and various types of lymphoma. This early phase 1 study is designed to assess how the drug behaves in the body and to monitor any side effects, helping to understand its potential for treating these difficult conditions. Participants will receive INCA036873 intravenously at doses defined by the study protocol. The study includes several parts: dose escalation to find the appropriate dose, dose expansion to further evaluate safety, and a pharmacodynamic cohort to study the drug's effects. The treatment is given according to these phases, and all participants receive the investigational drug without placebo comparison. Throughout the study, participants will undergo regular assessments including scans and blood tests to measure disease status and drug levels. Researchers will track dose limiting toxicities during the first 28 days and monitor treatment-emergent adverse events for up to about two years and 90 days. They will also measure how the drug is processed in the body and evaluate disease response over time, ensuring careful safety monitoring during and after treatment.
CONDITIONS
Brief Title
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG performance status of 0 or 1
- Histologically confirmed clear cell renal cell carcinoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, peripheral T-cell lymphoma (including NOS and ALCL), or cutaneous T-cell lymphoma (including MF or SS stage IIB or higher with B0/B1 blood involvement)
- Disease progression, relapse, or refractory to prior therapy (at least 1 prior line including ICI + TKI for ccRCC; at least 2 prior lines including immunochemotherapy and salvage for DLBCL/HGBCL; at least 1 prior systemic therapy for PTCL/CTCL)
- Measurable disease by RECIST v1.1, Lugano 2014, or ISCL/USCLC/EORTC criteria
- Tumor tissue available for central testing
You will not qualify if you...
- Untreated or progressive central nervous system disease unless previously treated and stable
- Other active invasive malignancy within 2 years except certain low-risk cancers
- Prior CD70-targeting therapy including CAR T-cell therapy
- Autologous stem cell transplant or CAR T-cell therapy within 12 weeks before enrollment
- Prior organ or allogeneic transplant
- Unresolved grade 2 or higher toxicity from prior therapy with exceptions
- Primary immunodeficiency or active autoimmune disease requiring immunosuppression
- Active hepatitis B, hepatitis C, HIV, or other chronic infections requiring systemic therapy
- Pregnancy, breastfeeding, or unwillingness to use effective contraception
- Other protocol-defined criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 2 years and 90 days
Participants receive INCA036873 administered intravenously at the protocol defined dose.
Visits occur regularly during treatment as per protocol
Trial Site Locations
Total: 22 locations
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California, United States, 92037
Not Yet Recruiting
3
University of Michigan
Ann Arbor, Michigan, United States, 48109
Not Yet Recruiting
4
The University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Not Yet Recruiting
5
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Not Yet Recruiting
6
Scri Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
7
Vanderbilt Medical Center
Nashville, Tennessee, United States, 37232
Not Yet Recruiting
8
Md Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
9
Macquarie University Hospital
Sydney, New South Wales, Australia, 02109
Actively Recruiting
10
Princess Alexandra Hospital Australia
Woolloongabba, Queensland, Australia, 04102
Actively Recruiting
11
Cancer Research Sa
Adelaide, South Australia, Australia, 05000
Actively Recruiting
12
Peter Maccallum Cancer Centre-Royal Melbourne Hospital
Melbourne, Victoria, Australia, 03000
Actively Recruiting
13
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium, 01200
Not Yet Recruiting
14
Universitair Ziekenhuis Antwerpen
Edegem, Belgium, 02650
Not Yet Recruiting
15
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, Belgium, 09000
Not Yet Recruiting
16
Universitair Ziekenhuis Leuven
Leuven, Belgium, 03000
Not Yet Recruiting
17
Aarhus University Hospital
Aarhus, Denmark, 08200
Not Yet Recruiting
18
Rigshospitalet Uni of Hospital of Copenhagen
Copenhagen, Denmark, DK-2100
Not Yet Recruiting
19
Aou Policlinico S. Orsola-Malpighi
Bologna, Italy, 40138
Not Yet Recruiting
20
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy, 20133
Not Yet Recruiting
21
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
Rome, Italy, 00168
Not Yet Recruiting
22
Centro Ricerche Cliniche Di Verona
Verona, Italy, 37134
Not Yet Recruiting
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here